摘要
目的探讨玻璃体腔注射雷珠单抗后青光眼阀植入在新生血管青光眼的治疗效果。方法选取我院在2017年8月-2018年8月期间接诊的新生血管青光眼患者共50名,随机分为2组,对照组和研究组各25名患者,对照组采用玻璃体腔注射雷珠单抗来治疗新生血管青光眼,研究组采用玻璃体腔注射雷珠单抗和青光眼阀植入来治疗新生血管青光眼,观察并记录两组新生血管青光眼患者的治疗效果。结果采用玻璃体腔注射雷珠单抗的研究组患者的治疗效果优于采用玻璃体腔注射雷珠单抗的对照组患者(P<0.05)。结论采用玻璃体腔注射雷珠单抗和青光眼阀植入来治疗新生血管青光眼,可以快速、安全、有效地治疗青光眼,使患者的视力在短期内得到提高,有效地解除患者的痛苦,大大减少手术并发症的发生,利于患者的痊愈,值得在各大医院推广使用。
Objective To explore the therapeutic effect of the glaucoma valve implantation after intravitreal injection of ranibizumab for neovascular glaucoma.Methods It selected 50 patients with neovascular glaucoma in our hospital from Aug.2017 to Aug.2018 who were randomly divided into control group and research group with 25 patients for each.The control group adopted the intravitreal injection of ranibizumab for neovascular glaucoma,and the research group adopted the intravitreal injection of ranibizumab and glaucoma valve implantation for neovascular glaucoma.It observed and recorded the treatment effect of patients neovascular glaucoma in two groups.Results The treatment effect in the study group was better than that in the control group(P<0.05).Conclusions The method of the intravitreal injection of ranibizumab and glaucoma valve implantation for neovascular glaucoma is fast,safe and effective in the treatment of glaucoma,improve the patient's vision in short term,effectively relieve the pain of the patients,and greatly reduce the occurrence of surgical complications,is beneficial to the patient's recovery and worth popularizing in hospitals.
作者
乐敬宝
王立涛
LE Jing-bao;WANG Li-tao(Department of Ophthalmology,The People's Hospital of Xishuangbanna Dai Autonomous Prefecture,Xishuangbanna Yunnan 666100,China)
出处
《云南医药》
2021年第5期434-436,共3页
Medicine and Pharmacy of Yunnan
关键词
玻璃体腔
雷珠单抗
青光眼阀植入
新生血管青光眼
vitreous body cavity
ranibizumab
glaucoma valve implantation
neovascular glaucoma
